Clinical pharmacology of novel anticancer agents: Focus on oral formulations

Keyphrases

• Oral Formulation 100%
• Ritonavir 100%
• Clinical Pharmacology 100%
• Novel Anticancer Agent 100%
• Agent Focus 100%
• Dose-limiting Toxicity 75%
• Docetaxel 75%
• Stable Disease 75%
• Oral Docetaxel 50%
• Paclitaxel 50%
• Anticancer Agents 50%
• Phase II Study 50%
• Response to Treatment 50%
• Further Development 50%
• Thrombocytopenia 50%
• Antitumor Activity 50%
• Monotherapy 50%
• Best Response 50%
• Partial Response 50%
• Pimasertib 50%
• Clinically Significant 25%
• Clinical Practice 25%
• Taxanes 25%
• Antitumor Efficacy 25%
• Diarrhea 25%
• Oral Bioavailability 25%
• P-glycoprotein (P-gp) 25%
• Low Water Solubility 25%
• Cytochrome P450 3A4 (CYP3A4) 25%
• Lipase 25%
• Combination Treatment 25%
• Maximum Tolerated Dose 25%
• Solid Dispersion Formulation 25%
• Dose Reduction 25%
• Water Solubility 25%
• Premature Discontinuation 25%
• Solid Dispersion 25%
• Nausea-vomiting 25%
• Dose Interruption 25%
• Oral Paclitaxel 25%
• First-pass Effect 25%
• Metronomic Schedule 25%
• Phase I Dose-escalation Trials 25%
• Oral Use 25%
• MEK Inhibitor (MEKi) 25%
• Low Oral Bioavailability 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Pharmacology 100%
• Anticarcinogen 100%
• Docetaxel 100%
• Ritonavir 80%
• Paclitaxel 60%
• Disease 60%
• Tablet 40%
• Antitumor Activity 40%
• Pimasertib 40%
• Bioavailability 40%
• Thrombocytopenia 40%
• Monotherapy 40%
• Taxane 20%
• Pancreatic Lipase 20%
• CYP3A4 20%
• Diarrhea 20%
• Prematurity 20%
• Mitogen Activated Protein Kinase Kinase Inhibitor 20%
• Protein P53 20%
• Nausea and Vomiting 20%
• Neoplasm 20%
• Maximum Tolerated Dose 20%
• First Pass Effect 20%